Familial amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Familial amyloidosis}} | {{Familial amyloidosis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{F.K}} | ||
==Overview== | ==Overview== | ||
Laboratory findings in amyloidosis include elevated [[erythrocyte sedimentation rate]], increased [[BUN]] level, serum [[creatinine]], [[protein]], [[Urinary casts|casts]], or fat cast in [[urine]]. Serum [[troponin]], [[B-type natriuretic peptide]], and [[beta-2-microglobulin]] are prognostic markers for [[heart failure]]. We may also have elevated level of [[AST]], [[ALT]], [[bilirubin]], [[ALP]], and [[TSH]]. | |||
Laboratory findings in amyloidosis include elevated [[erythrocyte sedimentation rate]], increased [[BUN]] level, serum [[creatinine]], protein, casts, or fat | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Cardiac | '''Cardiac''' | ||
* [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | * [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. They provide a quantitative assessment for [[Heart|cardiac]] damage and wall strain.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref><ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid25378951">{{cite journal |vauthors=Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J |title=Systemic AA amyloidosis: epidemiology, diagnosis, and management |journal=Clin Epidemiol |volume=6 |issue= |pages=369–77 |date=2014 |pmid=25378951 |pmc=4218891 |doi=10.2147/CLEP.S39981 |url=}}</ref> | ||
:* Troponin I or Troponin T | :*[[Troponin I]] or [[Troponin T]] | ||
:* BNP and NT-proBNP | :*[[BNP]] and [[NT-proBNP]] | ||
Hepatic | '''Hepatic''' | ||
* Common [[Test|tests]] that are abnormal in [[liver function tests]] including: | |||
* [[ | :*[[AST]] | ||
:*[[ALT]] | |||
:*Total [[bilirubin]] | |||
:*[[Alkaline phosphatase]] | |||
:*[[Albumin]] | |||
'''Renal''' | |||
* Common [[Test|tests]] that are abnormal in renal function [[Test|tests]] including: | |||
Renal | |||
* | |||
:*[[Creatinine|Serum creatinine]] | :*[[Creatinine|Serum creatinine]] | ||
| Line 78: | Line 33: | ||
:*[[Albumin]] to [[creatinine]] ratio in the [[urine]] | :*[[Albumin]] to [[creatinine]] ratio in the [[urine]] | ||
Thyroid | '''Thyroid''' | ||
* Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | * Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | ||
:* | :*[[TSH]] | ||
:*[[Free T4]] | |||
* | |||
: | : | ||
==References== | ==References== | ||
Latest revision as of 18:16, 25 November 2019
|
Familial amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Familial amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Familial amyloidosis laboratory findings |
|
Risk calculators and risk factors for Familial amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
Laboratory findings in amyloidosis include elevated erythrocyte sedimentation rate, increased BUN level, serum creatinine, protein, casts, or fat cast in urine. Serum troponin, B-type natriuretic peptide, and beta-2-microglobulin are prognostic markers for heart failure. We may also have elevated level of AST, ALT, bilirubin, ALP, and TSH.
Laboratory Findings
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis. They provide a quantitative assessment for cardiac damage and wall strain.[1][2][3]
- Troponin I or Troponin T
- BNP and NT-proBNP
Hepatic
- Common tests that are abnormal in liver function tests including:
Renal
- Serum creatinine
- Urinary protein
- Glomerular filtration rate
- Albumin to creatinine ratio in the urine
Thyroid
- Common tests that are abnormal in thyroidal involvement of amyloidosis include:
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clin Epidemiol. 6: 369–77. doi:10.2147/CLEP.S39981. PMC 4218891. PMID 25378951.